JOHNS HOPKINS HOSPITAL CANCER REGISTRY

Slides:

Advertisements

Similar presentations

Sylvia Le April 29, Disparities in Health Care Disparities in health care have serious impact on the quality of health care. Identifying health.

Advertisements

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

I.1 ii.2 iii.3 iv.4 1+1=. i.1 ii.2 iii.3 iv.4 1+1=

SEER PATTERNS OF CARE Kimberly Kimbler, MS, CCRP, CTR Kentucky Cancer Registry

How are cancer statistics kept up to date?.  Example:  Dx stage II colon cancer  Cancer has metastasized to the liver – 2009  How does the.

Impact of Cancer Diagnosis and Chemotherapy on Mammography Use Xinhua Yu, M.B., Ph.D. A. Marshall McBean, M.D., M.Sc. Beth A. Virnig, Ph.D., M.P.H Division.

Prognostic factors for breast cancer survival in affluent and deprived areas Jasmina Stefoski-Mikeljevic.

Breast Cancer By George Rezk.

Racial/Ethnic Disparities in Cancer Incidence, Survival and Treatment Linda C. Harlan, PhD, MPH National Cancer Institute Division of Cancer Control and.

FEMALE BREAST CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/03/20014.

Birga Terlunen-Traboldt ENT-Journal Club Need for Neck dissection after Radiochemotherapy? A study of the French GETTEC Group Vedrine P;Thariat J;Hitier.

Casefinding & Follow-Up Dolores E. McCord, RHIT, CTR Piedmont Hospital Atlanta, Georgia.

Lung Cancer Emily Cauchon Katie Reeves Emily Cauchon Katie Reeves.

THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/02/2013.

PROSTATE CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 09/01/2013.

CANCER INCIDENCE IN NEW JERSEY BY COUNTY, for the Comprehensive Cancer Control Plan County Needs Assessments August 2003 Prepared by: Cancer.

MELANOMA JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.

A Glimpse of the Science Behind the American Cancer Society Access to Care Campaign Impact of Being Uninsured or Underinsured on Individuals with Cancer.

LUNG CANCER Johns Hopkins Hospital Lung Cancer, Non-Small Cell , All Cases n=1364 Analytic - Initially Diagnosed and/or received all.

PANCREATIC CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY 2009.

SEER Provided Data Mohammad Afnan Baqai 12/3/2009.

THYROID CANCER JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/16/20014.

Differential Diagnoses September 25, You are a psychologist who has been referred 5 cases from the local school district. You have been asked to.

Treatment Patterns in the Management of Prostate Cancer: Lessons Learned from the Florida Cancer Data System Vonetta L. Williams, PhD, MPH, CTR June 23,

GASTRIC CANCER JHH Johns Hopkins Hospital Gastric Cancer , All Cases n=317 Analytic - Initially Diagnosed and/or received all or.

ANALYTIC LUNG CANCER by CLASS N = 351 Class 0: Dx’d at JHH only 1: Dx’d at JHH and received all/part of 1st course tx at JHH 2: Dx’d at an outside facility.

The Burden of Cancer in Connecticut Lou Gonsalves Connecticut Tumor Registry

Cancer Committee Meeting May 11, 2015 Cancer Liaison Physician Report Karen Lisa Smith MD MPH.

HEAD/NECK CARCINOMA Johns Hopkins Hospital.

S ARCOMA Diana Marroquin Period 1. W HAT IS SARCOMA ? A type of cancer that develops from certain tissues, like bone or muscle that can spread by extension.

National Cancer Intelligence Network Outcome and the effect of age in 1318 patients with synovial sarcoma: Report from the National Cancer Intelligence.

Quality & Sustainability in Cancer Control: A System Performance Spotlight Report To use a hyperlink, right click on it and select ‘Open Hyperlink’, or.

Presented at the NAACCR Annual Conference Quebec City June 22, 2010.

Johns Hopkins Hospital Cancer Registry Melanoma

JHH Prostate Cancer Prostate Cancer Cases Diagnosed 1999 – 2004 Analytic vs. Non-Analytic n=7776 * Analytic - Initially Diagnosed and/or received.

Virginia Cancer Registrars Association and Virginia Cancer Registry Annual Meeting October 3, 2007.

DEPT OF RADIATION ONCOLOGY Prognostic Value of Post-Radiotherapy FDG PET in Head and Neck Cancer after Intensity Modulated Radiation Treatment Heming Lu.

The Role of the HCC Cancer Registry in Facilitating Cancer Research Linda Cope, CTR HCC Registry Coordinator

Omega Best Cancer Hospital - India

Lung Cancer Angel.

What does the data tell us? Colorectal CANCER IN NEVADA

Fig. 1 Frequency distribution of initial palliative treatment modalities used. EBRT, external beam radiotherapy. Initial palliative treatment modality.

NON-SMALL CELL LUNG CANCER

Age and Racial/Ethnic Disparities in the Diagnosis of Breast Cancer in an Urban Population Joanne K. Fagan PhD, Denise Fyffe, PhD, Nadine Jenkins, CTR,

Presented By Deborah Schrag at 2016 ASCO Annual Meeting

Johns Hopkins Hospital Malignant and Benign Brain/CNS

A graph of the 15-year survival curves comparing localized melanoma (Stages I and II), regional metastases (Stage III), and distant metastases (Stage IV).

JOHNS HOPKINS CANCER REGISTRY 2009

ANALYTIC PANCREATIC CANCER by CLASS N = 369

Johns Hopkins Hospital Cancer Registry

Shared Positive Affect Shared Negative Affect

Surgical Cancer Treatment

تهیه کننده: استاد مربوطه: بهار 1392

Estimated current cancer incidence

Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study Stephen H. Culp, Paul.

Nirav S. Kapadia, MD, MS, Luca F. Valle, MD, Julie A

4155 primary hepatocellular carcinoma with known diagnosis month/year

Treating Leukemia in Youths

National Cancer Statistics in Korea, 2015

Caitlin C. Murphy, Kristin Wallace, Robert S. Sandler, John A. Baron

Megan Eguchi, MPh Sana karam, md, phd

NAACCR/IACR Combined Annual Conference 2019

Lung Cancer (C33-C34): 2011 Proportion of Cases Diagnosed at Each Stage, Adults (Aged 15-99), England and Wales Stage Adults Stage I 14.5% Stage II 7.3%

Arti Parikh-Patel, PhD MPH Cyllene Morris, DVM MPVM

OncotypeDX DCIS test use and clinical utility: A SEER population-based study Yao Yuan, PhD, MPH, Alison Van Dyke, MD, PhD, Serban Negoita, MD, DrPH & Valentina.

Shared Positive Affect Shared Negative Affect

Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.

Trevor D. Thompson NAACCR Conference 2019 Mathematical Statistician

Extracapsular Extension in Oropharyngeal Carcinoma: The HPV Era

Presentation transcript:

JOHNS HOPKINS HOSPITAL CANCER REGISTRY HEAD AND NECK CANCER 2011-2015 JOHNS HOPKINS HOSPITAL CANCER REGISTRY Prepared by Theresa SanLorenzo-Caswell, CTR 10/4/2016

HEAD/NECK OF THE SKIN ANALYTIC vs. NON-ANALYTIC by YEAR N = 1800 HEAD AND NECK CANCER 2011-2015 ALL CASES = 1428 ANALYTIC vs. NON-ANALYTIC

HEAD/NECK OF THE SKIN AGE AT DIAGNOSIS, ALL CASES N = 1800 HEAD AND NECK CANCER 2011-2015 ALL CASES = 1428 AGE AT DIAGNOSIS BY GENDER AGE AT DIAGNOSIS FOR 0-19 VERIFIED

HEAD AND NECK CANCER 2011-2015 ALL CASES = 1428 GENDER BY YEAR

HEAD AND NECK CANCER 2011-2015 ALL CASES = 1428 RACE/ETHNICITY BY GENDER

HEAD AND NECK CANCER 2011-2015 ALL CASES 1428 STATE OF RESIDENCE AT DIAGNOSIS

HEAD AND NECK CANCER 2011-2015 ALL MARYLAND CASES = 862 COUNTY OF RESIDENCE AT DIAGNOSIS

HEAD AND NECK CANCER 2011-2015 ANALYTIC CASES HEAD AND NECK CANCER 2011-2015 ANALYTIC CASES* - 1230 AJCC STAGE BY GENDER *Excludes Class 0- Cases diagnosed at JHH; treatment elsewhere

HEAD AND NECK CANCER 2011-2015 ANALYTIC CASES* = 1230 AJCC STAGE *Excludes Class 0 – Diagnosed at JHH; treatment elsewhere

HEAD AND NECK CANCER 2011-2015 ANALYTIC CASES* = 1257 SUBSITE BY GENDER *Includes class 0 – Diagnosed at JHH; all treatment elsewhere

HEAD AND NECK CANCER 2011-2015 ANALYTIC CASES TREATMENT BY STAGE AJCC 0 (47) AJCC I (255) AJCC II (129) AJCC III (200) AJCC IV (566) Surgery 80.9 78.0 48.1 32.0 14.0 Radiation 6.4 1.2 7.0 3.5 0.9 Chemotherapy 2.1 0.8 Surgery & Radiation 16.1 24.8 22.0 16.6 Surgery & Chemotherapy 0.5 Radiation & Chemotherapy 10.1 20.0 31.1 Surgery, Radiation & Chemotherapy 2.7 8.4 21.0 30.2 All Other Combinations Not Treated 4.2 3.3 100% STAGE IV 2 – REFUSED TREATMENT 12- DIED BEFORE TREATMENT 1 – CONTRAINDICATED 4 - RECOMMENDED UNKNOWN IF TRT GIVEN STAGE I 1 – REFUSED 1 – RECOMMENDED UNKNOWN IF DONE STAGE 0 2 - REFUSED

HEAD AND NECK 5-YEAR OBSERVED SURVIVAL 2003-2008 JHH vs. SEER vs. NCDB* ©2016 NCDB (*NCDB survival reports cannot be publicly reported on any website or publication) ©SEER; SEER*STAT

HEAD AND NECK 5-YEAR OBSERVED SURVIVAL 2003-2008 JHH vs. SEER vs. NCDB* ©2016 NCDB (*NCDB survival reports cannot be publicly reported on any website or publication) ©SEER; SEER*STAT

HEAD AND NECK 5-YEAR OBSERVED SURVIVAL 2003-2008 JHH vs. SEER vs. NCDB* ©2016 NCDB (*NCDB survival reports cannot be publicly reported on any website or publication) ©SEER; SEER*STAT

HEAD AND NECK 5-YEAR OBSERVED SURVIVAL 2003-2008 JHH vs. SEER vs. NCDB* ©2016 NCDB (*NCDB survival reports cannot be publicly reported on any website or publication) ©SEER; SEER*STAT